Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts
Fiche publication
Date publication
novembre 2008
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARBERI-HEYOB Muriel, Pr CHASTAGNER Pascal, Dr PINEL Sophie, Pr TAILLANDIER Luc
Tous les auteurs :
Labussiere M, Aarnink A, Pinel S, Taillandier L, Escanye JM, Barberi-Heyob M, Bernier-Chastagner V, Plenat F, Chastagner P
Lien Pubmed
Résumé
Malignant glioma patients have a life expectancy reduced to about 15 months despite aggressive surgery, radiotherapy (IRT), and chemotherapy. Doxorubicin has shown a marked cytotoxic effect against malignant glioma cells in vitro. The brain exposure to this drug is, however, hindered by the blood-brain barrier. Encapsulation of doxorubicin in liposomal carriers has been shown to reduce toxicities and to improve brain tumors exposure to doxorubicin. In this study, we evaluated the radiosensitizing properties of a nonpegylated liposomal doxorubicin (Myocet, MYO) on two subcutaneous (U87 and TCG4) and one intracranial (U87) malignant glioma models xenografted on nude mice. Doxorubicin biodistribution was assessed by a high-performance liquid chromatography method. Antitumor efficacy was investigated by tumor volume measurements and mice survival determination. We showed that (i) encapsulation of doxorubicin ensured a preferential deposition of doxorubicin in tumoral tissue in comparison with free doxorubicin; (ii) doxorubicin accumulated in both subcutaneous and intracranial tumors during repeated injections of MYO and this accumulation was linked to the potentiation of RT efficacy on two subcutaneous models; (iii) MYO was unable to improve the antitumoral efficacy of RT on an intracranial glioma model. Finally, this study emphasizes the importance of performing preclinical studies on models closer as possible of human tumors and localization to be more predictive of therapeutic effects observed in humans. Anti-Cancer Drugs 19:991-998 (c) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Référence
Anticancer Drugs. 2008 Nov;19(10):991-8.